This statistic displays the major currently approved therapies for multiple sclerosis (MS) as of 2014 in the United States, by annualized relapse rate (ARR). During this year, EMD Serono's Rebif, approved in 2002, had an ARR of 32 percent. There are about 350,000 to 500,000 people in the country that are diagnosed with the disease. MS is a disease that damages nerve cells in the brain and spinal cord which disrupts the ability of the nervous system to communicate with the body.
Selected approved multiple sclerosis therapies as of 2014, ranked by ARR*
Product (company, year of approval, route)
Annualized relapse rate relative risk reduction over 2 years
* ARR = annualized relapse rate.
** For mitoxantrone, the primary outcome measure for efficacy in the progressive types of MS was a composite of five elements: Expanded Disability Status Scale (EDSS) scores, Ambulation Index, number of relapses requiring treatment with steroids, months to first relapse needing treatment with steroids, and Standard Neurological Status. Data in the table for mitoxantrone have been extracted from the study; however, these were not the primary outcome measures.
***ARR for Tecfidera ranges from 44 to 53.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Catamaran. (July 1, 2014). Selected approved multiple sclerosis therapies as of 2014, ranked by ARR* [Graph]. In Statista. Retrieved November 10, 2024, from https://www-statista-com.ezproxy.canberra.edu.au/statistics/372312/ms-approved-therapies-in-the-us-by-arr/
Catamaran. "Selected approved multiple sclerosis therapies as of 2014, ranked by ARR* ." Chart. July 1, 2014. Statista. Accessed November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/372312/ms-approved-therapies-in-the-us-by-arr/
Catamaran. (2014). Selected approved multiple sclerosis therapies as of 2014, ranked by ARR* . Statista. Statista Inc.. Accessed: November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/372312/ms-approved-therapies-in-the-us-by-arr/
Catamaran. "Selected Approved Multiple Sclerosis Therapies as of 2014, Ranked by Arr* ." Statista, Statista Inc., 1 Jul 2014, https://www-statista-com.ezproxy.canberra.edu.au/statistics/372312/ms-approved-therapies-in-the-us-by-arr/
Catamaran, Selected approved multiple sclerosis therapies as of 2014, ranked by ARR* Statista, https://www-statista-com.ezproxy.canberra.edu.au/statistics/372312/ms-approved-therapies-in-the-us-by-arr/ (last visited November 10, 2024)
Selected approved multiple sclerosis therapies as of 2014, ranked by ARR* [Graph], Catamaran, July 1, 2014. [Online]. Available: https://www-statista-com.ezproxy.canberra.edu.au/statistics/372312/ms-approved-therapies-in-the-us-by-arr/
